Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Syndax Pharma up 21%

Published 03/14/2018, 01:02 PM
Updated 03/14/2018, 01:02 PM
© Reuters.  Syndax Pharma up 21%
  • Thinly traded micro cap Syndax Pharmaceuticals (SNDX +20.6%) is up a 4x surge in volume. No particular news accounts for the action, although it is between presentations at investor conferences. On Monday, March 12, it presented a corporate overview at Cowen's healthcare event and next Wednesday, March 21, it will do the same at Oppenheimer's.
  • The company forecasts $86M - 96M in operating expenses this year. Quick assets totaled $133.2M at year-end 2017.
  • The company is currently investigating the safety and efficacy of lead drug entinostat, in combination with other anti-cancer agents, in a range of cancers.
  • Previously: Syndax advances study of etinostat and Keytruda; shares ahead 12% premarket (May 17, 2017)
  • Now read: Arcadia up 257% on development milestones for healthier wheat


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.